Brepocitinib (PF-06700841)
Systemic Lupus Erythematosus (SLE)
Key Facts
About Priovant Therapeutics
Priovant Therapeutics is an emerging biotech player advancing a pipeline of oral small molecule therapies for severe autoimmune disorders. The company's core asset is brepocitinib, a dual TYK2/JAK1 inhibitor licensed from Pfizer, which is in Phase 3 development for systemic lupus erythematosus (SLE) and non-infectious uveitis. Backed by a strategic partnership with Roivant Sciences, Priovant is positioned to rapidly advance its targeted immunology portfolio in markets with significant commercial potential. The company operates as a private, pre-revenue entity with a focused team driving late-stage clinical development.
View full company profileAbout Priovant Therapeutics
Priovant Therapeutics is an emerging biotech player advancing a pipeline of oral small molecule therapies for severe autoimmune disorders. The company's core asset is brepocitinib, a dual TYK2/JAK1 inhibitor licensed from Pfizer, which is in Phase 3 development for systemic lupus erythematosus (SLE) and non-infectious uveitis. Backed by a strategic partnership with Roivant Sciences, Priovant is positioned to rapidly advance its targeted immunology portfolio in markets with significant commercial potential. The company operates as a private, pre-revenue entity with a focused team driving late-stage clinical development.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus (SLE) Drugs
| Drug | Company | Phase |
|---|---|---|
| hCDR1 (Edratide) | XTL Biopharmaceuticals | Phase 2 |
| Nipocalimab | johnson-and-johnson-innovative-medicine | Phase 3 |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| IFNα Kinoid (IFN-K) | Neovacs | Phase IIb |
| aiSLE® DX Flare Risk Index | Progentec Diagnostics | Commercial |
| aiSLE® DX Disease Activity Index | Progentec Diagnostics | Commercial |
| OASIS Study (Digital Biomarkers) | Progentec Diagnostics | Clinical Study |
| RSLV-132 | Resolve Therapeutics | Phase 2 |
| Mini-CAR for SLE | Caravan Biologix | Pre-clinical |
| Internal Program | BenevolentAI | Preclinical |
| Telitacicept (RC18) | RemeGen | Approved |
| Cenerimod | Ono Pharmaceutical | Phase 3 |